Lannett Company, Inc.
|$934 M||Market Cap|
|10.4%||EBIT / EV|
|4.4%||FCF / EV|
|33.4%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|The EBIT / Enterprise Value of 10.4% ranks as Very High.|
|The Free Cash Flow / Enterprise Value of 4.4% ranks as Average.|
|The Return on Invested Capital Value of 13.1% ranks as Average.|
|The Cash Return on Capital Value of 5.5% ranks as Below Average.|
|The 3 Year Average Revenue Growth Value of 33.4% ranks as Very High.|
|Near-term Financial Health appears to be Very Good. The Current Ratio is 2.52.|
Lannett Co., Inc. engages in the development, manufacture, market, and distribution of generic pharmaceutical products. Its pharmaceutical products are distributed to drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations. It also provides laboratory services which involves analytical, development, stability, and product identification; product formulation; granulation blending; encapsulation; compression; coating; and packaging. The company was founded in 1942 and is headquartered in Philadelphia, PA.
|Valvoline Inc. (VVV)|
|Procter & Gamble Company (PG)|
|McDonald's Corporation (MCD)|
|Fiat Chrysler Automobiles N.V. (FCAU)|
|Baozun Inc Sponsored ADR Class A (BZUN)|
|Vector Group Ltd. (VGR)|
|New Stocks Added!|